# US 2025/0144024 A1 · Bendamustine solid dispersions and continuous infusion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144024 A1
- Document ID: US20250144024A1
- Status: Published application
- Kind: A1
- Application number: 19/018,156
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2014-03-13
- Inventors: Vasilios VOUDOURIS
- Web page: https://patentgrep.com/patent/US20250144024A1

## CPC

- A61K 9/10: Dispersions; Emulsions
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are pharmaceutical compositions comprising nitrogen mustard, for example bendamustine hydrochloride, solid dispersions substantially free of degradants. Also provided are methods of producing and administering nitrogen mustards and in particular bendamustine hydrochloride solid dispersions substantially free of degradants. The pharmaceutical compositions can be used for any disease that is sensitive to treatment with bendamustine hydrochloride, such as neoplastic diseases.

## Claims

### Claim at position 1

1-94. (canceled)

### Claim 95

A method of treating a medical condition in a patient, wherein the medical condition is selected from the group consisting of chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, diffuse large B-cell lymphoma, breast cancer, small cell lung cancer, and autoimmune disease, the method comprising the steps of:
a. contacting a stream of an aqueous intravenous infusion solution continuously flowing at a controlled rate with a stream of a second, non-aqueous, solution comprising a nitrogen mustard compound continuously flowing at a second controlled rate, wherein the nitrogen mustard compound is selected from the group consisting of bendamustine, cyclophosphamide, chlorambucil, melphalan, uramustine, ifosfamide, mechlorethamine and salts and combinations thereof;
b. mixing the solutions to provide a uniform and continuously flowing stream of a mixed solution which provides a pharmaceutical dose of 0.2 to 4.0 mg/ml of the nitrogen mustard compound; and
c. administering the mixed solution to the patient, thereby administering the pharmaceutical dose of the nitrogen mustard compound to the patient, wherein the residence time period of the solutions from contacting to administering is 30, 20, 10 or 5 seconds or less.
